IL297684B1 - Processes for preparing a kinase inhibitor - Google Patents
Processes for preparing a kinase inhibitorInfo
- Publication number
- IL297684B1 IL297684B1 IL297684A IL29768422A IL297684B1 IL 297684 B1 IL297684 B1 IL 297684B1 IL 297684 A IL297684 A IL 297684A IL 29768422 A IL29768422 A IL 29768422A IL 297684 B1 IL297684 B1 IL 297684B1
- Authority
- IL
- Israel
- Prior art keywords
- processes
- preparation
- kinase inhibitor
- kinase
- inhibitor
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B43/00—Formation or introduction of functional groups containing nitrogen
- C07B43/06—Formation or introduction of functional groups containing nitrogen of amide groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063017739P | 2020-04-30 | 2020-04-30 | |
| PCT/US2021/030035 WO2021222673A1 (en) | 2020-04-30 | 2021-04-30 | Processes for the preparation of a kinase inhibitor |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL297684A IL297684A (en) | 2022-12-01 |
| IL297684B1 true IL297684B1 (en) | 2026-03-01 |
Family
ID=76076455
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL297684A IL297684B1 (en) | 2020-04-30 | 2022-10-26 | Processes for preparing a kinase inhibitor |
| IL324105A IL324105A (en) | 2020-04-30 | 2025-10-21 | Processes for the preparation of a kinase inhibitor |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL324105A IL324105A (en) | 2020-04-30 | 2025-10-21 | Processes for the preparation of a kinase inhibitor |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US12497367B2 (https=) |
| EP (1) | EP4143169B1 (https=) |
| JP (2) | JP7728795B2 (https=) |
| KR (1) | KR20230005190A (https=) |
| CN (2) | CN115461328B (https=) |
| AU (1) | AU2021263474A1 (https=) |
| BR (1) | BR112022021712A2 (https=) |
| CA (1) | CA3176042A1 (https=) |
| CL (1) | CL2022003008A1 (https=) |
| CO (1) | CO2022015205A2 (https=) |
| CR (1) | CR20220551A (https=) |
| GE (1) | GEP20267875B (https=) |
| IL (2) | IL297684B1 (https=) |
| MX (1) | MX2022013528A (https=) |
| PE (1) | PE20230110A1 (https=) |
| PH (1) | PH12022552821A1 (https=) |
| TW (1) | TWI887405B (https=) |
| WO (1) | WO2021222673A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN117402114A (zh) * | 2018-01-26 | 2024-01-16 | 埃克塞里艾克西斯公司 | 用于治疗激酶依赖性病症的化合物 |
| TW202334090A (zh) * | 2021-11-03 | 2023-09-01 | 美商艾克塞里克斯公司 | 用於治療激酶依賴性病症之化合物 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019148044A1 (en) * | 2018-01-26 | 2019-08-01 | Exelixis, Inc. | Compounds for the treatment of kinase-dependent disorders |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1154105A (zh) * | 1994-06-08 | 1997-07-09 | H·隆德贝克有限公司 | 4-芳基-1-(二氢化茚甲基、二氢苯并呋喃甲基或二氢苯并噻吩甲基)哌啶、-四氢吡啶或哌嗪类化合物 |
| ZA954689B (en) | 1994-06-08 | 1996-01-29 | Lundbeck & Co As H | 4-Aryl-1-(indanmethyl dihydrobenzofuranmethyl or dihydrobenzothiophenemethyl) piperidines tetrahydropyridines or piperazines |
| CN101466672B (zh) * | 2006-06-12 | 2012-05-16 | 诺瓦提斯公司 | N-羟基-3-[4-[[[2-(2-甲基-1h-吲哚-3-基)乙基]氨基]甲基]苯基]-2e-2-丙烯酰胺的盐 |
| NZ572547A (en) | 2006-06-12 | 2011-06-30 | Novartis Ag | SALTS OF N-HYDROXY-3-[4-[[[2-(2-METHYL-1H-INDOL-3-yl)ETHYL]AMINO]METHYL]PHENYL]-2E-2-PROPENAMIDE |
| JP5486606B2 (ja) * | 2008-11-13 | 2014-05-07 | エクセリクシス， インク． | キノリン誘導体の調製方法 |
| NZ779754A (en) * | 2009-01-16 | 2023-04-28 | Exelixis Inc | Malate salt of n-(4-{ [6,7-bis(methyloxy)quinolin-4-yl] oxy} phenyl)-n’-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, and crystalline forms thereof for the treatment of cancer |
| EA030435B1 (ru) | 2010-07-16 | 2018-08-31 | Экселиксис, Инк. | ТАБЛЕТКА, СОДЕРЖАЩАЯ МОДУЛЯТОР c-MET В ФОРМЕ КРИСТАЛЛИЧЕСКОЙ L-МАЛАТНОЙ СОЛИ (ВАРИАНТЫ), СПОСОБ ЕЕ ПРОИЗВОДСТВА И СПОСОБ ЛЕЧЕНИЯ ОНКОЛОГИЧЕСКОГО ЗАБОЛЕВАНИЯ С ЕЕ ИСПОЛЬЗОВАНИЕМ |
| CN104395284A (zh) | 2011-10-20 | 2015-03-04 | 埃克塞里艾克西斯公司 | 制备喹啉衍生物的方法 |
| EP3174854B1 (en) | 2014-07-31 | 2022-08-24 | Exelixis, Inc. | Method of preparing fluorine-18 labeled cabozantinib and its analogs |
| CR20250117A (es) | 2018-01-26 | 2025-05-09 | Exelixis Inc | COMPUESTOS PARA EL TRATAMIENTO DE TRASTORNOS DEPENDIENTES DE CINASAS (Divisional 2020-0355) |
| CA3088198A1 (en) | 2018-01-26 | 2019-08-01 | Exelixis, Inc. | Compounds for the treatment of kinase-dependent disorders |
| KR102828472B1 (ko) * | 2018-12-13 | 2025-07-03 | 엑셀리시스, 인코포레이티드 | 키나아제 억제제의 결정질 형태 및 염 형태 |
| CN109761899B (zh) | 2019-02-14 | 2022-11-15 | 广州六顺生物科技股份有限公司 | 喹啉衍生物、其药学上可接受的盐或其溶剂合物、其应用、药物及药物组合物 |
-
2021
- 2021-04-30 CN CN202180031136.7A patent/CN115461328B/zh active Active
- 2021-04-30 MX MX2022013528A patent/MX2022013528A/es unknown
- 2021-04-30 KR KR1020227037607A patent/KR20230005190A/ko active Pending
- 2021-04-30 EP EP21727657.5A patent/EP4143169B1/en active Active
- 2021-04-30 CN CN202511511945.4A patent/CN121591655A/zh active Pending
- 2021-04-30 CA CA3176042A patent/CA3176042A1/en active Pending
- 2021-04-30 JP JP2022566135A patent/JP7728795B2/ja active Active
- 2021-04-30 AU AU2021263474A patent/AU2021263474A1/en active Pending
- 2021-04-30 US US17/922,208 patent/US12497367B2/en active Active
- 2021-04-30 PH PH1/2022/552821A patent/PH12022552821A1/en unknown
- 2021-04-30 CR CR20220551A patent/CR20220551A/es unknown
- 2021-04-30 PE PE2022002513A patent/PE20230110A1/es unknown
- 2021-04-30 WO PCT/US2021/030035 patent/WO2021222673A1/en not_active Ceased
- 2021-04-30 TW TW110115786A patent/TWI887405B/zh active
- 2021-04-30 GE GEAP202516101A patent/GEP20267875B/en unknown
- 2021-04-30 BR BR112022021712A patent/BR112022021712A2/pt unknown
-
2022
- 2022-10-26 IL IL297684A patent/IL297684B1/en unknown
- 2022-10-26 CO CONC2022/0015205A patent/CO2022015205A2/es unknown
- 2022-10-28 CL CL2022003008A patent/CL2022003008A1/es unknown
-
2025
- 2025-06-20 JP JP2025104881A patent/JP2025128388A/ja active Pending
- 2025-10-21 IL IL324105A patent/IL324105A/en unknown
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019148044A1 (en) * | 2018-01-26 | 2019-08-01 | Exelixis, Inc. | Compounds for the treatment of kinase-dependent disorders |
Also Published As
| Publication number | Publication date |
|---|---|
| CN115461328A (zh) | 2022-12-09 |
| GEP20267875B (en) | 2026-03-25 |
| EP4143169B1 (en) | 2026-04-15 |
| JP2025128388A (ja) | 2025-09-02 |
| CL2022003008A1 (es) | 2023-06-23 |
| TW202208335A (zh) | 2022-03-01 |
| MX2022013528A (es) | 2022-11-16 |
| PH12022552821A1 (en) | 2024-02-12 |
| CR20220551A (es) | 2022-12-07 |
| CN121591655A (zh) | 2026-03-03 |
| US20230192619A1 (en) | 2023-06-22 |
| EP4143169A1 (en) | 2023-03-08 |
| CN115461328B (zh) | 2025-11-07 |
| CO2022015205A2 (es) | 2022-10-31 |
| PE20230110A1 (es) | 2023-01-25 |
| IL297684A (en) | 2022-12-01 |
| BR112022021712A2 (pt) | 2022-12-06 |
| IL324105A (en) | 2025-12-01 |
| AU2021263474A1 (en) | 2022-11-17 |
| US12497367B2 (en) | 2025-12-16 |
| JP2023524692A (ja) | 2023-06-13 |
| WO2021222673A1 (en) | 2021-11-04 |
| JP7728795B2 (ja) | 2025-08-25 |
| TWI887405B (zh) | 2025-06-21 |
| CA3176042A1 (en) | 2021-11-04 |
| KR20230005190A (ko) | 2023-01-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GB201914860D0 (en) | Inhibitor compounds | |
| GB202008201D0 (en) | Inhibitor compounds | |
| IL267393A (en) | Crystal forms of a Janus kinase inhibitor | |
| ZA202109183B (en) | Novel compounds for inhibition of janus kinase 1 | |
| IL288484A (en) | Crystalline salt forms of a kinase inhibitor | |
| IL289929A (en) | Crystal forms of cd73 inhibitor | |
| EP4126878A4 (en) | COMPOUNDS AS CASEIN KINASE INHIBITORS | |
| EP4289847A4 (en) | PIM KINASE INHIBITOR | |
| IL313548A (en) | MET kinase inhibitors | |
| PT4157831T (pt) | Processos de preparação de um inibidor de jak1 | |
| IL297684B1 (en) | Processes for preparing a kinase inhibitor | |
| IL290087A (en) | inhibitory substances | |
| GB202004960D0 (en) | Inhibitor compounds | |
| IL291221A (en) | Methods for the synthesis of wolbenzine | |
| GB202110373D0 (en) | Inhibitor compounds | |
| GB201905328D0 (en) | Inhibitor compounds | |
| GB202300881D0 (en) | Inhibitor compounds | |
| GB202107905D0 (en) | Processes for the preparation of inhibitory compounds | |
| IL285427A (en) | Crystal forms of jak2 inhibitor | |
| IL288982A (en) | Macrocyclic kinase inhibitor polymorphs | |
| HK40090033A (en) | Processes for the preparation of a kinase inhibitor | |
| GB202307924D0 (en) | Inhibitor compounds | |
| IL307826A (en) | Processes for the synthesis of valbanazine | |
| IL286054A (en) | A process for the preparation of a modified imidazoquinoline | |
| HK40073322A (en) | Polymorphs of a macrocyclic kinase inhibitor |